DRIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
DarioHealth Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$4.49−0.33 (-6.85%)
Close on Oct 19, 2026
- Market cap
- $41.95M
- P/E (TTM)
- 1.1
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
56.6%+23.5 pts over 5 years
Operating margin
-163.9%+230.8 pts over 5 years
Net margin
-186.6%+202.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -17.3% | -6.8% | +24.2% | +39.1% | |
| Gross profit | -4.5% | +9.5% | +38.2% | – | |
| EPS, diluted | -17.5% | +58.5% | +20.3% | -18.3% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 268.1% | -125.2% | -59.6% | |
| Return on assets | -243.3% | -98.2% | -36.4% | |
| Current ratio | 1.00 | 4.85 | 3.76 | |
| Debt to equity | – | – | 0.45 | |
| Interest coverage | – | – | -12.1× | |
| Inventory turnover | 4.9× | 2.7× | 2.1× | |
| Capex to revenue | 28.8% | 1.6% | 0.6% | |
| Diluted shares | 0M | 6M | 4M |
Where the cash went
Fiscal 2021 to 2025, five years combined
DarioHealth generated $193.14M from operations and spent $1.70M on capital expenditure, dividends and share buybacks. 92% of that went back into the business.
Generated
$193.14M
Used
$1.70M
Capital expenditure$1.57M92%Dividends$00%Share buybacks$134.00K8%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-186.6%
×Asset turnover0.20×
×Equity multiplier1.64×
=Return on equity, FY2025-59.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -186.6% | 0.20× | 1.64× | -59.6% |
| FY2024 | -158.1% | 0.25× | 1.65× | -65.7% |
| FY2023 | -292.0% | 0.19× | 1.56× | -86.0% |
| FY2022 | -224.9% | 0.25× | 1.33× | -75.1% |
| FY2021 | -374.2% | 0.30× | 1.20× | -135.0% |
| FY2020 | -388.7% | 0.25× | 1.27× | -125.2% |
| FY2019 | -234.6% | 0.39× | 1.39× | -127.5% |
| FY2018 | -240.8% | 0.70× | 1.64× | -276.7% |
| FY2017 | -304.5% | 0.95× | -4.17× | 1211.0% |
| FY2016 | -388.4% | 0.63× | -1.10× | 268.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$41.71M
- Cash generatingOperating cash flow above zero-$25.94M
- Return on assets improvedROA up on the prior year-44.3% → -35.1%
- Earnings backed by cashOperating cash flow above net income-$25.94M vs -$41.71M
- Less leverageLong-term debt to assets fell19.7% → 27.9%
- Better liquidityCurrent ratio rose2.44 → 3.76
- No dilutionShare count did not rise2M → 4M
- Gross margin improvedGross margin up on the prior year49.06% → 56.64%
- More efficientAsset turnover rose0.28 → 0.19